'Promising' Status For Faron's Traumakine In UK Opens Possibilities For Early Access, Pricing Negotiations
Executive Summary
The UK regulator has granted a "promising designation" to Faron Pharmaceuticals' Traumakine acute respiratory distress syndrome treatment, which means the orphan drug may be made available to patients pre-approval under the early access scheme. The drug is currently in Phase III in the EU and Japan, with 420 moderate to severe ARDS patients expected to be treated.